Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Karl Sorger, Ph.D.

Profile Picture
Other Positions

Harvard College, Cambridge MAA.B1984Biochemistry
Cambridge University, Cambridge UKPhD1987Biochemistry
UCSF-Varmus Lab, San FranciscoPosdoc1993Cancer Biology
A.B. Summa Cum Laude, Hoopes Prizes for Undergraduate Thesis
Ph.D. in Biochemistry
Director, Cell Decision Processes Center

Research in the Sorger Lab focuses on signal transduction networks controlling cell proliferation and death, dysregulation of these networks in cancer and inflammation and mechanisms of action of therapeutic drugs targeting signaling proteins. His group uses mathematical and experimental approaches to construct and test computational models of oncogenic and signaling networks in cell lines, patient-derived cells and murine disease models. The Sorger Lab also develops open-source software for analyzing biological networks and drug mechanism of action and it participates in multiple collaborative programs working to improve data access and reproducibility. Recent research extends a systems pharmacology approach to high-dimensional analysis of biopsy samples and the interpretation of clinical trials.

As founding head of the Harvard Program in Therapeutic Science (HiTS) and its Laboratory Systems Pharmacology (LSP) Peter leads a multi-institutional effort to advance the basic and translational science used to develop new medicines, create novel drug combinations and identify responsive patients. The LSP applies systems approaches to understanding and mitigating adverse drug effects and to designing new clinical trials. The recently established Harvard-MIT Center of Regulatory Sciences focuses on improving how drugs are evaluated, brought to market and used in patients. HiTS includes faculty from seven institutions.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U2CCA233262 (SORGER, PETER KARL) Sep 30, 2018 - Jun 30, 2023
    Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)
    Role: Principal Investigator
  2. R01AG058063 (ALBERS, MARK W) Sep 30, 2018 - May 31, 2023
    Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimers Disease
    Role: Co-Principal Investigator
  3. U54CA225088 (SORGER, PETER KARL) Mar 8, 2018 - Feb 28, 2023
    Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs
    Role: Principal Investigator
  4. R56AG058063 (ALBERS, MARK W) Sep 30, 2017 - Sep 29, 2018
    Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimer's Disease
    Role: Co-Principal Investigator
  5. U54HL127365 (SORGER, PETER KARL) Sep 10, 2014 - Jun 30, 2021
    Pharmaco Response Signatures and Disease Mechanism
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Jain A, Gyori BM, Hakim S, Bunga S, Taub DG, Ruiz-Cantero MC, Tong-Li C, Andrews N, Sorger PK, Woolf CJ. Nociceptor neuroimmune interactomes reveal cell type- and injury-specific